Randomiserade studier bör tolkas med omsorg

Lakartidningen

Volumn 97, Issue 9, 2000, Pages 1004-1007

  Lindeberg, Staffan ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INDUSTRY; DRUG UTILIZATION; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; DRUG INDUSTRY; DRUG UTILIZATION; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 17544403220     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Godlee F, ed. Clinical evidence. London: BMJ Publishing Group, 1999; vol 1.
2. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60.
3. van Buchem FL, Knottnerus JA, Schrijnemaekers VJ, Peeters MF. Primary care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis. Lancet 1997; 349: 683-7.
4. Geelhoed GC, Turner J, Macdonald WB. Efficacy of a small single dose of oral dexamethasone for outpatient croup: a double blind placebo controlled clinical trial. BMJ 1996; 313: 140-2.
5. Vercoulen JH, Swanink CM, Zitman F, Vreden SG, Hoofs MP, Fennis JF et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996; 347: 858-61.
6. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-13.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published erratum appears in Lancet 1998; 352:1557]. Lancet 1998; 352: 854-65.
9. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 1998; 280: 605-13.
10. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9.
11. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
12. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-72.
13. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
14. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971; 218: 1400-10.
15. Peto R. Failure of randomisation by »sealed» envelope. Lancet 1999; 354: 73.